Glenmede Trust’s Celldex Therapeutics CLDX Stock Holding History

Glenmede Trust’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$419K	Hold	11,267	–	–	﹤0.01%	1052
2026 Q1	$357K	Buy	+11,267	New	+$307K	﹤0.01%	1086
2018 Q2	–	Sell	-195	Closed	-$8K	–	1978
2018 Q1	$8K	Hold	195	–	–	﹤0.01%	2245
2017 Q4	$8K	Buy	+195	New	+$8.35K	﹤0.01%	2245
2016 Q3	–	Sell	-47	Closed	-$3K	–	2588
2016 Q2	$3K	Hold	47	–	–	﹤0.01%	2320
2016 Q1	$2K	Hold	47	–	–	﹤0.01%	2386
2015 Q4	$10K	Hold	47	–	–	﹤0.01%	2064
2015 Q3	$7K	Hold	47	–	–	﹤0.01%	2196
2015 Q2	$17K	Buy	+47	New	+$18.7K	﹤0.01%	1951
2014 Q2	–	Sell	-120	Closed	-$31K	–	2331
2014 Q1	$31K	Buy	120 +11	+10%	+$4.21K	﹤0.01%	1781
2013 Q4	$39K	Buy	+109	New	+$42K	﹤0.01%	1681

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Glenmede Trust's CLDX Position: Q2 2026 in Review

Glenmede Trust held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 11,267 shares worth $419K. The position accounts for ﹤0.01% of the portfolio, ranked #1052.

Glenmede Trust first reported a position in CLDX in Q4 2013 and has held it in 11 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Glenmede Trust held 11,267 shares of Celldex Therapeutics worth $419K as of Q2 2026.
Glenmede Trust left its Celldex Therapeutics share count unchanged in Q2 2026.
Celldex Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #1052 holding.
Glenmede Trust first reported a position in Celldex Therapeutics in Q4 2013 and has held it in 11 quarters since.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.